Blueprint for a Pop-up SARS-CoV-2 Testing Lab

Jennifer A. Doudna

is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04.11.20061424 doi: medRxiv preprint Supplementary Figure 2 . Clinical Validation, Contrived and Clinical Samples -one of duplicate PCR plates. The results from the corresponding duplicate PCR plate are shown in Figure 4 . Replicates are plotted as individual points (rather than mean values). An undetermined Ct value is plotted as Ct = 0. A : Contrived negative and local testing facility known negative samples (clinical testing site 1). Whole cell RNA purified from cultured human 293T cells was diluted in IGI's sample collection buffer (1X DNA/RNA Shield in PBS) to approximate negative samples. Human RNA concentration was calculated using UV absorbance, and the concentration was converted to an approximate copy number for comparison with positive RNA controls (See methods for details). Assay quality controls are shown in lanes 31-33, representing the extraction control (Thermo Fisher's MS2 control in 1X DNA/RNA shield and PBS), and two PCR controls -water, and the Thermo Fisher kit positive SARS-CoV-2 RNA control (without MS2 RNA). B : Contrived positive and local testing facility known positive samples. Contrived positive samples were prepared by diluting SARS-CoV-2 positive control RNA from Thermo Fisher's kit into IGI's sample collection buffer (1X DNA/RNA Shield in PBS). Assay quality controls are the same as in B.